Selection for Oncotype Dx testing among young women with early-stage ER+/HER2-breast cancer.

被引：3
|
作者：
Poorvu, Philip Daniel
Gelber, Shari I.
Rosenberg, Shoshana M.
Ruddy, Kathryn Jean
Tamimi, Rulla
Peppercorn, Jeffrey M.
Schapira, Lidia
Borges, Virginia F.
Come, Steven E.
Collins, Laura C.
Warner, Ellen
Partridge, Ann H.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin, Dept Oncol, Rochester, MN USA
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Stanford Canc Ctr, Palo Alto, CA USA
[6] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
[7] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[8] Harvard Med Sch, Boston, MA USA
[9] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
533
引用
收藏
页数：2
相关论文
共 50 条
  • [21] APOBEC driving genomic evolution in ER+/HER2-breast cancer
    Bos, M.
    Smid, M.
    Sleijfer, S.
    Martens, J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S105 - S106
  • [22] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Vialel, G.
    Curigliano, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 347 - 354
  • [23] Evaluation of Oncotype DX testing and subsequent patterns of care in patients (pts) with early-stage breast cancer (ESBC).
    Fitzgerald, Meghan
    Hassell, Robert
    Haislip, Sally
    Gilmore, James W.
    Richardson, Steve
    Cooper, Joseph
    Szabo, Stephen
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Aromatase inhibitor failure: predictors and time to first failure among women with metastatic ER+/HER2-breast cancer in the US
    Thomson, E.
    Namjoshi, M.
    Landsman-Blumberg, P.
    Chu, B. C.
    CANCER RESEARCH, 2012, 72
  • [25] Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer
    Yahiya Y. Syed
    Molecular Diagnosis & Therapy, 2020, 24 : 621 - 632
  • [26] Hormone receptor alterations and treatment responses after neoadjuvant therapy in patients with ER+/HER2-breast cancer.
    Maeda, Shigeto
    Tohyama, Hiroaki
    Tokai, Yukiko
    Nakashima, Kazuaki
    Kamohara, Yukio
    Nagata, Yasuhiro
    Ito, Masahiro
    Fujioka, Hikaru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Evaluation of PgR status by immunohistochemistry may be inferior to PgR results by Oncotype DX for assessing the recurrence risk in ER+/HER2-breast cancer with low or intermediate tumor proliferation
    Sinn, Peter
    Kriegsmann, Mark
    Felten, Ute
    Wacker, Juergen
    Schneeweiss, Andreas
    Varga, Zsuzsanna
    CANCER RESEARCH, 2015, 75
  • [28] Oncotype Dx Score, HER2 Low Expression, and Clinical Outcomes in Early-Stage Breast Cancer: A National Cancer Database Analysis
    Roy, Arya Mariam
    Jiang, Changchuan
    Perimbeti, Stuthi
    Deng, Lei
    Shapiro, Charles L.
    Gandhi, Shipra
    CANCERS, 2023, 15 (17)
  • [29] Characterization of oncotype DX recurrence score and chemotherapy utilization patterns in young women (≤40) with early stage ER plus /HER-, lymph node negative breast cancer
    Sammons, Sarah
    Ren, Yi
    Force, Jeremy
    Fayanju, Oluwadamilola M.
    Rosenberger, Laura H.
    Plichta, Jennifer K.
    Kimmick, Gretchen
    Westbrook, Kelly
    Dent, Susan
    Anders, Carey
    Thomas, Samantha M.
    Hyslop, Terry
    Hwang, E. S.
    Marcom, P. K.
    Greenup, Rachel A.
    CANCER RESEARCH, 2020, 80 (04)
  • [30] Surveillance testing after early-stage breast cancer.
    Keating, NL
    Landrum, MB
    Guadagnoli, E
    Winer, EP
    Ayanian, JZ
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2005, 20 : 206 - 206
12345